BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By | 2016-03-28T17:53:52+00:00 August 19th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) x June 30, 2015

[FORM 10-Q (Mark One) x June 30, 2015 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Ronghua Wang EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period. Qinghua Liu Qinghua Liu Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By | 2016-03-28T17:55:55+00:00 August 19th, 2015|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: June 30, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-03-28T17:57:26+00:00 August 17th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[The Company’s board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the “Special Committee”), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Company’s shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger] [EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section] [Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K]

By | 2016-03-24T02:26:21+00:00 August 14th, 2015|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments
Read More

WX [WuXi PharmaTech (Cayman)] 6-K: The Company’s board of directors, acting upon the

[The Company’s board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the “Special Committee”), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Company’s shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger] [EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section] [Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K]

By | 2016-03-24T02:27:41+00:00 August 14th, 2015|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321063015.htm]

By | 2016-03-28T19:15:38+00:00 August 14th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: FORM 10-Q (Mark One) x June 30, 2015

[FORM 10-Q (Mark One) x June 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321063015.htm]

By | 2016-03-28T19:16:55+00:00 August 14th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results · · Pageview: 1308 BEIJING, August 4, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the second quarter, ended June 30, 2015, after market close on Wednesday, August 12,] [Sinovac Announces Results of 2015 Annual General Meeting of Shareholders · · Pageview: 447 BEIJING, August 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC. The required quorum, a majority of] [Sinovac Reports Unaudited Second Quarter Financial Results -- Conference call scheduled for Thursday, August 13, 2015 at 8:00 AM ET · · Pageview: 254 BEIJING, Aug.12, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2015. Second] []

By | 2016-03-16T06:23:53+00:00 August 13th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More
Skip to toolbar